VC trio de­buts seed fund; Take­da cuts ear­ly gene ther­a­py work; Bio­gen’s new face of BD; Biotech in­vestors get hands on; and more

Wel­come back to End­points Week­ly, your re­view of the week’s top bio­phar­ma head­lines. Want this in your in­box every Sat­ur­day morn­ing? Cur­rent End­points read­ers can vis­it their read­er pro­file to add End­points Week­ly. New to End­points? Sign up here.

By now, most, if not all, of you will have heard about the ex­cit­ing news that End­points has joined the Fi­nan­cial Times fam­i­ly. Thank you for all of your sup­port over the years — and now, on­to greater things!

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.